Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market.
Mankind Pharma inks licensing pact with Innovent to commercialise Sintilimab in India
Share it
Related Article
